VivoSeq
Other

Plexiform Neurofibroma

19

Pipeline Programs↗

7

Active Trials↗

11

Companies Involved↗

Plexiform Neurofibroma is an emerging landscape with 19 programs across 11 companies. The most active players are Bristol-Myers Squibb, Light Sciences Oncology, Merck & Co.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

10/100

Completion Rate

73/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1L

Light Sciences Oncology

1 program

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 2S

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

17 of 19 classified programs — the dominant modality here.

11%ALL OTHERSProtein / enzyme15%Gene therapy15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 95% of 20 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed11 · 50%
Terminated4 · 18%
Not yet recruiting3 · 14%
Active, not recruiting3 · 14%
Recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06188741·200 enrolled
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT04924608·145 enrolled
Treatment of NF1-related Plexiform Neurofibroma With Trametinib
Active, not recruiting·—·Phase 2·NCT03741101·15 enrolled
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Active, not recruiting·SSpringWorks Therapeutics, Inc.·Phase 2·NCT03962543·114 enrolled
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT07407803·177 enrolled
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
Not yet recruiting·WWest China Hospital·Phase 2·NCT06763315·50 enrolled
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Not yet recruiting·GGirish Dhall, MD·Phase 1·NCT06502171·30 enrolled
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Completed·IIndiana University·Phase 2·NCT01673009·36 enrolled
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
Completed·National Institutes of Health Clinical Center (CC)·Phase 1·NCT00253474·36 enrolled
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Completed·IIndiana University·Phase 1·NCT01275586·6 enrolled
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Completed·National Cancer Institute (NCI)·Phase 2·NCT00076102·36 enrolled
Study of PEG-Intron for Plexiform Neurofibromas
Completed·UUniversity of Pittsburgh·Phase 2·NCT00396019·86 enrolled
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01412892·30 enrolled
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Completed·—·Phase 2·NCT00030264·23 enrolled
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT03231306·45 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)